1(14)
|
2017/ Iran |
Randomized controlled clinical trial, n = 49 women. |
Continuous consumption of 1 gram of ginger 2 times/day, for 6 cycles, by patients undergoing platinum treatment (carboplatin and paclitaxel). |
There were no differences between the control group and the intervention group (p = 0,57). |
2(15)
|
2017/ Australia |
Double-blind, randomized placebo-controlled trial, n = 51 (19 men and 32 women). |
A dose of 1.2 g of ginger 4 times/day, for 5 days, in 3 cycles, by chemotherapy patients with emetogenic potential from moderate to high. |
There was no significant difference between the placebo group and the intervention group (p > 0.05) concerning nausea and emesis. There were also no differences between the groups concerning the use of aprepitant (p > 0,05). |
3(16)
|
2017/ Thailand |
Double-blind, randomized placebo-controlled phase II study, n = 96 (21 men and 75 women). |
Consumption of 10 g of ginger 2 times/day, for 4 days, in 4 cycles, by chemotherapy patients with emetogenic potential from moderate to high. |
The emesis was lower in the experimental group (p < 0.001), similar to grade 3 vomiting (p = 0.001). The intensity of nausea was lower in the experimental group (mild, > 17%; moderate, > 39%; and severe, > 34%; p = 0.001). |
4(17)
|
2016/ Thailand |
Randomized controlled, double-blind, crossover study, n = 34 women. |
1 g ginger, 2 times/day, for 5 days, in the 2nd and 3rd cycles, by patients undergoing treatment with doxorubicin and cyclophosphamide. |
Emesis: p = 0.5. There was no statistically significant difference in the use of rescue medication, considering a significance level of 5%. |
5(18)
|
2017/ Italy |
Randomized, double-blind, placebo-controlled multicenter study, n = 244 (160 men and 84 women). |
1 g ginger, 4 times/day, for 19 or 27 days during 2 cycles by patients undergoing cisplatin treatment. |
In the 1st cycle, mean FLIE score on day 1: p = 0.147. In the 2nd cycle, mean FLIE score on day 1: p = 0.675. In the 1st cycle, day 2: p = 0.782. In the 2nd cycle, day 2: p = 0.733. In the 1st cycle delayed nausea: p = 0.851. In the 2nd cycle delayed nausea: p = 0.379. Therefore, both cycles (1st and 2nd) did not present statistically significant differences considering significance level of 5%. |
6(19)
|
2016/ Thailand |
Prospective, randomized, placebo-controlled study, n = 150 women. |
1 g ginger, 4 times/day, for 3 days during 3 cycles by patients undergoing treatment with Doxorrubicicin/cyclophosphamide; cyclophosphamide/Doxorrubicicin/5-Fluorouracil; Docetaxel/ Doxorrubicicin/cyclophosphamide. |
In the 1st cycle nausea: experimental group (1.36); control group (1.46) .2nd cycle nausea: experimental group (1.36); control group (1.32). 3rd cycle nausea: experimental group (1.42), control group (1.37); therefore, nausea was higher in the group that used ginger in the 2nd and 3rd cycle. Reduction of emesis in the experimental group from 1.4 to 0.71. |
7(20)
|
2016/ Thailand |
Randomized, double-blind clinical trial, n = 65 women. |
1 g of ginger, 2 times/day, for 10 days from the 2nd cycle. |
Ginger was not effective for the management of nausea (p = 0.238), but it demonstrated benefits in the incidence of vomiting (p <0.0001). |
8(21)
|
2015 / Turkey |
Randomized and controlled experimental study, n = 60 women. |
Ginger consumption for 3 days, no further specifications. |
The incidence of emesis and intensity of nausea were lower in the experimental group (p <0.05). Nevertheless, the incidence of nausea did not change between groups. |
9(22)
|
2015/ Australia |
Double-blind, randomized placebo-controlled study, n = 53. |
A dose of 1.2 g of ginger, 4 times/day, for 5 days, by chemotherapy patients with emetogenic potential from moderate to high. |
There were no significant differences between groups regarding adverse effects (p> 0.05). |
10(23)
|
2014/ Thailand |
Randomized, double-blind, controlled clinical trial, n = 87. |
Consumption of 10 mg of ginger, 2 times/day, for 4 cycles, by chemotherapy patients with emetogenic potential from moderate to high. |
Significant reduction in the occurrence of acute (p = 0.013) and delayed emesis (p < 0,001), acute nausea (p = 0.002) and delayed (p <0.001). |
11(24)
|
2013/ Iran |
Randomized, double-blind, placebo-controlled clinical trial, n = 80 women. |
1 g of ginger, 4 times / day, for 6 days. |
The incidence and intensity of anticipatory nausea were significantly lower in the experimental group (p = 0.0008 vs. p = 0.0007), as well as in acute nausea (incidence and intensity p = 0.0001). |
12(25)
|
2013/ Iran |
Randomized crossover clinical trial (1st cycle, n = 44; and 2nd cycle, n = 31. |
Consumption of 0.25 g of ginger, 4 times/day, for 2 cycles, by patients undergoing cisplatin treatment. |
In the 1st cycle, ginger reduced the intensity of nausea in the 1st hour by 9%; in the 2nd hour, by 18.2%; in the 3rd hour, by 13.7%; in the 4th hour, by 22.7%; and, at the end of 24 hours, by 27.3%. Concerning vomiting, in the 1st cycle, there was a reduction of 9.1% in the 1st hour, 9.1% in the 2nd hour, 9.1% in the 3rd hour, 4.6% in the 4th hour, and 4.7% in the final 24 hours. In the 2nd cycle, the intensity was lower in the control group. The value of p in both was> 0.05. |
13(26)
|
2012/ Iran |
Randomized, open pilot clinical trial, n = 100 women. |
Consumption of 1.5 g of ginger, 3 times/day, for 4 days, by patients undergoing treatment with docetaxel, epirubicin, cyclophosphamide. |
Experimental group: a significant decrease in the incidence of nausea in the period from 6 to 24 hours after chemotherapy (p = 0.04). In the first 6 hours, on the second, third, and fourth day after chemotherapy, there was no difference between the groups in the incidence of nausea, emesis (p> 0.05). |
14(27)
|
2012/ United States |
Randomized, double-blind, placebo-controlled clinical trial, n = 576 (55 men and 521 women). |
Consumption of 0.5 g, 1 g or 1.5 g of ginger for 1, 2 or 3 times / day, for 6 days for 3 cycles. |
Experimental group: reduction of acute nausea (p = 0.013 vs. 0.003). There was a reduction in anticipatory nausea (p <0.0001). The incidence of emesis in all patients was low (p = 0.5). |
15(28)
|
2011 / India |
Prospective study, n = 600 cycles. |
Consumption of 2 g of ginger for 3 days. |
All patients used ginger; of these, 5% had moderate to severe acute nausea, 5% had moderate to severe acute emesis, 15% had moderate to severe nausea and emesis. |
16(29)
|
2011 / India |
Prospective, randomized, double-blind and randomized institutional study, n = 60 (40 men and 20 women). |
Consumption of 1 or 2 g of ginger according to weight, 5 or 6 times/day, for 3 days up to 3 cycles, by patients undergoing cisplatin / doxorubicin treatment. |
Moderate to severe acute nausea was lower in the experimental group (p = 0,003). Moderate to severe acute emesis was lower in the experimental group (p = 0.002). Moderate to severe delayed nausea was lower in the experimental group (p <0.001). Moderate to severely delayed emesis was lower in the experimental group (p = 0.022). |
17(30)
|
2009/ United States |
Double-blind, randomized, phase II / III, placebo-controlled clinical trial, n = 644 (64 men and 580 women). |
Consumption of 0.5 g, 1 g, or 1.5 g of ginger for 3 times/day, for 6 days for 3 cycles. |
Experimental group: reduction of nausea (p = 0.003). Acute nausea: p < 0,001, significant reduction. |
18(31)
|
2009/ United States |
Randomized, double-blind, placebo-controlled clinical trial, n = 162 (40 men and 122 women). |
A dose of 1.2 g of ginger, 4 or 8 times/day, for 3 days, by chemotherapy patients with emetogenic potential from low to high. |
Acute nausea: without aprepitant, p = 0.47; with aprepitant, p = 0.55. Delayed nausea: without aprepitant, p = 0.69; with aprepitant, p = 0.01. Acute emesis: without aprepitant, p = 0.61; with aprepitant, p = 0.91. Delayed emesis: without aprepitant, p = 0.88; with aprepitant, p = 0.77. In the experimental group using aprepitant, the intensity of delayed nausea was higher (p = 0.01). At higher dosages of ginger (2 g), there was a higher incidence of delayed nausea (without aprepitant, n = 17; with aprepitant, n = 9). |
19(32)
|
2004/ Thailand |
Randomized controlled clinical trial, n = 48 women. |
Consumption of 1 g of ginger, 4 times/day, for 5 days up to the 2nd cycle, by patients undergoing cisplatin treatment. |
Nausea day 1: p = 0.875. Nausea day 2: p = 0.582. Nausea day 3: p = 0.865. Nausea day 4: p = 0.294. Nausea day 5: p = 0.554. Number of nausea days - from day 2 to day 5: p = 0.763. Control of emesis in the experimental group: p = 0.754. Considering a significance level of 5%, the results were not statistically significant. |
20(33)
|
2003 / India |
Randomized, prospective, crossover, double-blind study, n = 50 (11 men and 39 women). |
Consumption of 1 g ginger, 2 times/day, for 3 days during 2 cycles, by patients being treated with combined cyclophosphamide. |
Complete nausea control: with ginger (62%), metoclopramide (58%) and ondansetron (86%). Complete control of emesis: with ginger (68%), metoclopramide (64%) and ondansetron (86%). |
21(34)
|
2017 / China |
Randomized, double-blind, placebo-controlled clinical study, n = 140 (100 men and 40 women) |
Consumption of 0.5 g ginger, 2 times/day, for 5 days, by patients being treated with cisplatin. |
There was no significant difference between the experimental and control groups in decreasing the incidence and intensity of delayed nausea and emesis (p> 0.05). Delayed nausea: experimental group, 60.6%; control group, 72.5%. Delayed emesis: experimental group, 22.5%; control group, 26.1%. |
22(35)
|
2017/ Iran |
Randomized, double-blind, placebo-controlled clinical trial, n = 80 women. |
Consumption of 1 g of ginger, 4 times/day, for 6 days, by chemotherapy patients with emetogenic potential from low to high. |
The incidence of emesis was lower in the experimental group in the anticipatory (p = 0.04), acute (p = 0.04) and delayed (p = 0.003) period. |
23(36)
|
2017/ Iran |
Randomized, double-blind, placebo-controlled crossover clinical study, n = 36 (26 men and 10 women). |
Consumption of 1 g ginger, 4 times/day, for 3 days during 2 cycles, by patients being treated with cisplatin. |
Control of emesis: day 1 (experimental group, 42%; control group 25%), day 2 (experimental group, 25%; control group, 19%) and day 3 (experimental group, 19%; control group, 22%). Nausea control: day 1 (p = 0.14), day 2 (p = 0.31) and day 3 (p = 0.73), that is, p> 0.05. |
24(37)
|
2008/ United States |
Randomized, clinical study, n = 28. |
No specified dose, 2 times/day, for 3 days. |
There was a reduction in the incidence and intensity of delayed nausea in the experimental group, in addition to a decrease in the use of antiemetic drugs, but it was not statistically significant (p> 0.05). |